{"created":"2023-06-20T16:47:59.017534+00:00","id":19770,"links":{},"metadata":{"_buckets":{"deposit":"5c7c9958-aa42-4a06-bf50-a8e7e158645c"},"_deposit":{"created_by":3,"id":"19770","owners":[3],"pid":{"revision_id":0,"type":"depid","value":"19770"},"status":"published"},"_oai":{"id":"oai:kindai.repo.nii.ac.jp:00019770","sets":["14:2667:4459"]},"author_link":["33623"],"item_8_biblio_info_21":{"attribute_name":"書誌情報","attribute_value_mlt":[{"bibliographicIssueDates":{"bibliographicIssueDate":"2018","bibliographicIssueDateType":"Issued"},"bibliographicPageEnd":"4","bibliographicPageStart":"1","bibliographic_titles":[{"bibliographic_title":"科学研究費助成事業研究成果報告書 (2017)"}]}]},"item_8_description_33":{"attribute_name":"抄録","attribute_value_mlt":[{"subitem_description":"研究成果の概要（和文）：EGFR-TKIに耐性を示した後にﾆﾎﾞﾙﾏﾌﾞを使用したEGFR変異陽性非小細胞肺がん25例(T790M変異陽性8例)の有効性および免疫関連因子を検討した。陰性症例は陽性と比較して良好な有効性及び、PD-L1が高発現の傾向を示した。ﾆﾎﾞﾙﾏﾌﾞ使用症例9例の全ｴｸｿｰﾑ解析にてnon-synonymous mutation数を評価したところ、奏効例では有意にmutation数が高値であった。EGFR-TKI耐性症例に関しての耐性機序毎の抗PD-1抗体の有効性やnon-synonymous mutationを評価した初の報告であり、Annals of Oncology誌にて報告した。\n研究成果の概要（英文）：The efficacy of PD-1 blockade in EGFR mutated NSCLC with different mechanisms of acquired resistance to EGFR-TKIs is unknown. We retrospectively evaluated nivolumab efficacy and immune-related factors in such patients according to their status for the T790M resistance mutation of EGFR.We identified 25 patients with EGFR mutation-positive NSCLC who were treated with nivolumab. Whole-exome sequencing of tumor DNA was carried out to identify gene alterations. Efficacy of nivolumab tended to increase as the PD-L1 expression level increased with cutoff values of 10% and 50%.The proportion of tumors with a PD-L1 level of10% or50% was higher among T790M-negative patients than among -positive patients. Nivolumab responders had a significantly higher CD8+ TIL density and nonsynonymous mutation burden. T790M-negative patients with EGFR mutation-positive NSCLC are more likely to benefit from nivolumab after EGFR-TKI treatment, possibly as a result of a higher PD-L1 expression level.","subitem_description_type":"Abstract"}]},"item_8_description_36":{"attribute_name":"内容記述","attribute_value_mlt":[{"subitem_description":"研究種目：若手研究(B);  研究期間：2016～2017;   課題番号：16K21506;   研究分野：臨床腫瘍学;   科研費の分科・細目：","subitem_description_type":"Other"}]},"item_8_description_37":{"attribute_name":"資源タイプ","attribute_value_mlt":[{"subitem_description":"Research Paper","subitem_description_type":"Other"}]},"item_8_description_41":{"attribute_name":"フォーマット","attribute_value_mlt":[{"subitem_description":"application/pdf","subitem_description_type":"Other"}]},"item_8_publisher_14":{"attribute_name":"出版者 名前","attribute_value_mlt":[{"subitem_publisher":"近畿大学"}]},"item_8_relation_11":{"attribute_name":"著者 外部リンク","attribute_value_mlt":[{"subitem_relation_name":[{"subitem_relation_name_text":"https://kaken.nii.ac.jp/grant/KAKENHI-PROJECT-16K21506/"}]}]},"item_8_text_10":{"attribute_name":"著者 役割","attribute_value_mlt":[{"subitem_text_value":"研究代表者"}]},"item_8_text_7":{"attribute_name":"著者(英)","attribute_value_mlt":[{"subitem_text_language":"en","subitem_text_value":"HAYASHI, Hidetoshi"}]},"item_8_text_8":{"attribute_name":"著者 所属","attribute_value_mlt":[{"subitem_text_value":"近畿大学医学部; 講師"}]},"item_8_text_9":{"attribute_name":"著者所属(翻訳)","attribute_value_mlt":[{"subitem_text_value":"Kindai University"}]},"item_8_version_type_12":{"attribute_name":"版","attribute_value_mlt":[{"subitem_version_resource":"http://purl.org/coar/version/c_be7fb7dd8ff6fe43","subitem_version_type":"NA"}]},"item_creator":{"attribute_name":"著者","attribute_type":"creator","attribute_value_mlt":[{"creatorNames":[{"creatorName":"林, 秀敏"},{"creatorName":"ハヤシ, ヒデトシ","creatorNameLang":"ja-Kana"}],"nameIdentifiers":[{},{}]}]},"item_files":{"attribute_name":"ファイル情報","attribute_type":"file","attribute_value_mlt":[{"accessrole":"open_date","date":[{"dateType":"Available","dateValue":"2018-11-20"}],"displaytype":"detail","filename":"16K21506seika.pdf","filesize":[{"value":"197.3 kB"}],"format":"application/pdf","licensetype":"license_note","mimetype":"application/pdf","url":{"label":"16K21506seika.pdf","url":"https://kindai.repo.nii.ac.jp/record/19770/files/16K21506seika.pdf"},"version_id":"860a4379-054e-4b25-8ce8-91325670b06c"}]},"item_keyword":{"attribute_name":"キーワード","attribute_value_mlt":[{"subitem_subject":"バイオマーカー","subitem_subject_scheme":"Other"},{"subitem_subject":"個別化医療","subitem_subject_scheme":"Other"},{"subitem_subject":"免疫チェックポイント阻害薬","subitem_subject_scheme":"Other"}]},"item_language":{"attribute_name":"言語","attribute_value_mlt":[{"subitem_language":"jpn"}]},"item_resource_type":{"attribute_name":"資源タイプ","attribute_value_mlt":[{"resourcetype":"research report","resourceuri":"http://purl.org/coar/resource_type/c_18ws"}]},"item_title":"driver遺伝子異常肺癌に対する分子標的薬の耐性化と、抗PD1抗体の有効性","item_titles":{"attribute_name":"タイトル","attribute_value_mlt":[{"subitem_title":"driver遺伝子異常肺癌に対する分子標的薬の耐性化と、抗PD1抗体の有効性"},{"subitem_title":"Resistance mechanis of molecular targeted therapy and tumor micro environment as the immune-checkpoint inhibitor's biomarker","subitem_title_language":"en"}]},"item_type_id":"8","owner":"3","path":["4459"],"pubdate":{"attribute_name":"公開日","attribute_value":"2018-11-20"},"publish_date":"2018-11-20","publish_status":"0","recid":"19770","relation_version_is_last":true,"title":["driver遺伝子異常肺癌に対する分子標的薬の耐性化と、抗PD1抗体の有効性"],"weko_creator_id":"3","weko_shared_id":3},"updated":"2023-06-20T21:34:30.925013+00:00"}